Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Phase 3 Recruiting
1,210 enrolled
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Phase 3 Recruiting
304 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
CheckMate-1533
Phase 2 Recruiting
76 enrolled
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Phase 2 Recruiting
156 enrolled
LuCa-MERIT-1
Phase 1 Recruiting
320 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
eVOLVE-01
Phase 2 Recruiting
180 enrolled
INTerpath-13
Phase 2 Recruiting
180 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Phase 3 Recruiting
474 enrolled
IMMUNOLIFE2
Phase 2 Recruiting
162 enrolled
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Phase 3 Recruiting
851 enrolled
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Phase 2 Recruiting
318 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
880 enrolled
MK-3475-01E
Phase 2 Recruiting
60 enrolled
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Phase 1 Recruiting
12 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
340 enrolled
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Phase 2 Recruiting
105 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled
MK-3475-01A
Phase 1/2 Recruiting
450 enrolled
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Phase 2 Recruiting
42 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
Phase 2 Recruiting
51 enrolled
G360-IIT
Phase 2 Recruiting
108 enrolled
MK-3475-01G
Phase 2 Recruiting
90 enrolled
SPORADIC
Phase 2 Recruiting
152 enrolled
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Phase 2/3 Recruiting
30 enrolled
LUNG-05
Phase NA Recruiting
29 enrolled
NOVOCURE
Phase 1 Recruiting
30 enrolled
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Phase 2 Recruiting
59 enrolled
COMET
Phase 3 Recruiting
133 enrolled
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Phase 2 Recruiting
300 enrolled
PALACE
Phase 2 Recruiting
63 enrolled
ATHENEA
Phase 2 Recruiting
97 enrolled
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Phase 2 Recruiting
112 enrolled
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/2 Recruiting
203 enrolled
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 Recruiting
345 enrolled
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
Phase 2 Recruiting
24 enrolled
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 Recruiting
98 enrolled
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
Phase 2 Recruiting
84 enrolled
LEDANG
Phase 3 Recruiting
123 enrolled
LN-144
Phase 2 Recruiting
245 enrolled
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3 Recruiting
450 enrolled
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Phase 1 Recruiting
21 enrolled